Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis-Reference-Cited by-同舟云学术

Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis

Published:2019-06 Issue:6 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kim Yu Kyong¹^ORCID,Lee Juyoung²,Oh Jaeseong¹,Rhee Su-jin¹,Shin Seung Han³,Yoon Seo Hyun¹,Lee SeungHwan¹,Kim Han-Suk³,Yu Kyung-Sang¹

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea

2. Department of Pediatrics, Inha University College of Medicine, Incheon, Republic of Korea

3. Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Abstract

Fluconazole is an antifungal agent with reported evidence for its prophylactic effect against systemic fungal infection in preterm infants. The aim of this study was to build a population pharmacokinetic model to evaluate the pharmacokinetic characteristics of intravenous and oral fluconazole in preterm infants with the current prophylactic fluconazole dosing regimen.

Funder

National Research Foundation of Korea

Ministry of Food and Drug Safety

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01960-18

Reference58 articles.

1. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

2. Prophylaxis with Weekly Versus Daily Fluconazole for Fungal Infections in Patients with AIDS